Connor, Clark & Lunn Investment Management (CC&L)
NGM

Connor, Clark & Lunn Investment Management (CC&L)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
2024
Q1 		$156K Buy
2023
Q3 		– Sell
2023
Q2 		$315K Sell
2023
Q1 		$792K Buy
2022
Q4 		$775K Buy
2022
Q3 		$1.45M Buy
2022
Q2 		$462K Buy